Nardilysin-Regulated Scission Mechanism Activates Polo-like Kinase 3 to Suppress the Development of Pancreatic Cancer
J. Fu, J. Li, C.-F. Li, C.-L. Tsai, W. Yin, J. Hou, P. Chen, Y. Cao, Y. Kang, Y. Sun, X. Xia, K. Furukawa, Y. Lu, M. Wu, Q. Huang, J. Yao, D. H. Hawke, B.-F. Pan, J. Zhao, J. Huang, H. Wang, E. M. Bahassi, P. J. Stambrook, P. Huang, J. B. Fleming, , P. Chiao
Abstract
Pancreatic ductal adenocarcinoma (PDAC) develops through step-wise genetic and molecular alterations including Kras mutation and inactivation of apoptotic pathways. Here, we find that development of anoikis resistance and metastasis of KrasG12D-driven PDAC in mice is accelerated by deleting Plk3, explaining the often reduced Plk3 expression in human PDAC. Importantly, a 41 kDa Plk3 (p41Plk3) that contained the entire kinase domain at the N-terminus (1-353 aa) is activated by scission of the precursor p72Plk3 at Arg354 by metalloendopeptidase Nardilysin (NRDC), and the resulting p32Plk3 C-terminal Polo-box domain (PBD) was quickly removed by proteasome degradation preventing the p41Plk3 inhibition by PBD. We found that p41Plk3 is the activated form of Plk3 that regulates a feedforward mechanism to promote anoikis and suppress PDAC and metastasis. p41Plk3 phosphorylates c-Fos on Thr164, which in turn, induces expression of Plk3 and pro-apoptotic genes. These findings uncovered an NRDC-regulated post-translational mechanism (PTM) that activates Plk3, establishing a prototypic regulation by scission mechanism.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of p21-activated kinase 4 (PAK4) suppresses pancreatic tumor progression and metastasis through regulating E-cadherin
Kui‐Jin Kim, Cheng Hyun Lee, … Jin Won Kim·Cancer Gene TherapyPeer-reviewed·Oct 31, 2026
- KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development
S. L. Tinsley, R. A. Shelley, … B. Allen-Petersen·bioRxiv·Jul 1, 2023
- PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma
Garima Baral, Claire M. Pfeffer, … Brittany L. Allen-Petersen·bioRxiv·Jul 14, 2025
- Mena (ENAH) Promotes KRAS-Driven Tumor Growth and Metastatic Progression in Pancreatic Ductal Adenocarcinoma
Lina A. Ariyan, Érika Pereira Zambalde, … John Christopher McAuliffe·bioRxiv·Jan 8, 2026
- PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer
Sahar F. Bannoura, Husain Yar Khan, … Asfar S. Azmi·bioRxiv·Dec 10, 2025
- Nischarin agonist rilmenidine shows antimetastatic potential in pancreatic ductal adenocarcinoma
Kristina Živić, Marijana Pavlović, … Jelena Grahovac·bioRxiv·Oct 27, 2025